To test our hypothesis that CS2 may exhibit increased responsiveness to immunotherapy, we analyzed a clinical cohort of metastatic melanoma patients from Gide et al., who received either anti-PD1 monotherapy or a combination of anti-CTLA4 and anti-PD1 therapy. The gene discussed is CTLA4; the disease is metastatic melanoma.